GleamWall
中文EN

CERO CERO THERAPEUTICS HOLDINGS, INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1870404 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-259.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,130.6%
Debt / equity—
Current ratio0.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.61x
Accruals ratio157.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$1.97M$1.74M$2.34M—$2.39M$2.75M$2.91M$1.77M
SG&A expense$1.22M$2.11M$2.51M—$1.98M$1.97M$2.04M$2.63M
Operating income-$3.19M-$3.85M-$4.85M—-$4.36M-$4.72M-$4.95M-$4.40M
Interest expense$917,669$690,044$166,286————-$4,418
Net income$4.02M-$1.03M-$5.89M-$4.54M-$4.86M-$5.42M-$5.11M-$4.23M
EBITDA-$3.14M-$3.79M——-$4.29M-$4.65M-$4.87M-$4.29M
EPS (basic)0.06-0.70-0.20—-9.10-61.71-31.82-170.22
EPS (diluted)0.00-0.70-0.20—-9.10-61.71-31.82-170.22
Weighted avg. shares (diluted)1.09B42.18M28.76M—1.26M488,076171,38124,838
Banking
Deposits$196,000$609.00B$509.00B$1.30M————
Balance sheet
Cash & equivalents$455,925$862,756$857,489$1.66M$1.95M$3.23M$5.10M$3.38M
Current assets$975,003$1.55M$1.57M$2.73M$2.55M$4.25M$5.77M$3.71M
PP&E, net$71,312$125,947$184,449$246,148$313,452$382,806$452,227$624,900
Total assets$1.83M$1.90M$2.21M$3.64M$3.91M$6.20M$7.99M$6.49M
Current liabilities$20.32M$32.41M$11.33M$9.09M$8.45M$7.62M$7.86M$9.42M
Long-term debt——$136,765—————
Total debt——$136,765—————
Total liabilities$20.67M$32.41M$11.46M$9.09M$8.45M$7.84M$8.32M$10.19M
Shareholders' equity-$18.84M-$30.51M-$9.26M-$5.45M-$4.54M-$1.63M-$329,386-$3.70M
Net debt——-$720,724—————
Cash flow statement
Operating cash flow-$3.03M-$7.89M$2.80M-$3.83M-$3.21M———
Financing cash flow$2.75M———$1.42M———
Depreciation & amortization$54,635$58,502——$69,354$76,294$76,294$113,855
Stock-based compensation$121,936$1.12M$1.62M$259,666$348,116$183,328$304,946$400,000
Dividends paid——$127,144$0$0$0$127,144—

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.